BACKGROUND: Estrogen receptor (ER)-negative breast cancers have a worse prognosis than ER-positive cancers, being more aggressive and overexposed to stimuli leading to their progression. Hepatocyte growth factor (HGF) has been associated with proliferation, migration and invasion of tumor cells, and several tumors, including those of breast cancer, produce HGF and overexpress its receptor. Diacylglycerol kinases (Dgks), which phosphorylate diacylglycerol to phosphatidic acid, are key regulators of cell signaling. Our research was focused on their role in HGF-induced invasion of MDA-MB-231 cells, a model of ER-negative breast cancer. MATERIALS AND METHODS: Dgk activity was evaluated with a kinase assay, MDA-MB-231 cell invasion via culturing of cells in matrigel-coated transwells, and anchorage-independent growth was assessed using a soft agar assay. RESULTS: HGF induces Dgk activation in MDA-MB-231 cells that is required for cell invasiveness. Moreover, Dgks are involved in MDA-MB-231 anchorage-independent growth. CONCLUSION: Dgks could be a target for ER-negative breast cancer therapy.
BACKGROUND:Estrogen receptor (ER)-negative breast cancers have a worse prognosis than ER-positive cancers, being more aggressive and overexposed to stimuli leading to their progression. Hepatocyte growth factor (HGF) has been associated with proliferation, migration and invasion of tumor cells, and several tumors, including those of breast cancer, produce HGF and overexpress its receptor. Diacylglycerol kinases (Dgks), which phosphorylate diacylglycerol to phosphatidic acid, are key regulators of cell signaling. Our research was focused on their role in HGF-induced invasion of MDA-MB-231 cells, a model of ER-negative breast cancer. MATERIALS AND METHODS:Dgk activity was evaluated with a kinase assay, MDA-MB-231 cell invasion via culturing of cells in matrigel-coated transwells, and anchorage-independent growth was assessed using a soft agar assay. RESULTS:HGF induces Dgk activation in MDA-MB-231 cells that is required for cell invasiveness. Moreover, Dgks are involved in MDA-MB-231 anchorage-independent growth. CONCLUSION: Dgks could be a target for ER-negative breast cancer therapy.
Authors: James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman Journal: Adv Enzyme Regul Date: 2009-11-04
Authors: Stephen B Milne; Pavlina T Ivanova; Michelle D Armstrong; David S Myers; Jovana Lubarda; Yulia V Shulga; Matthew K Topham; H Alex Brown; Richard M Epand Journal: Biochemistry Date: 2008-08-15 Impact factor: 3.162
Authors: Federica Chianale; Elena Rainero; Cristina Cianflone; Valentina Bettio; Andrea Pighini; Paolo E Porporato; Nicoletta Filigheddu; Guido Serini; Fabiola Sinigaglia; Gianluca Baldanzi; Andrea Graziani Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205
Authors: Antonietta Fazio; Eric Owusu Obeng; Isabella Rusciano; Maria Vittoria Marvi; Matteo Zoli; Sara Mongiorgi; Giulia Ramazzotti; Matilde Yung Follo; James A McCubrey; Lucio Cocco; Lucia Manzoli; Stefano Ratti Journal: Int J Mol Sci Date: 2020-07-26 Impact factor: 5.923